Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
Julphar
Cipla
QuintilesIMS
Harvard Business School

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,794,410

« Back to Dashboard

Which drugs does patent 6,794,410 protect, and when does it expire?

Patent 6,794,410 protects AUBAGIO and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.

Summary for Patent: 6,794,410
Title: Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
Abstract:The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis. ##STR1##
Inventor(s): Wettstein; Joseph (Lebanon, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:10/113,078
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,794,410
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,794,410
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,794,410

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-001 Sep 12, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS ➤ Sign Up
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-002 Sep 12, 2012 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,794,410

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0123571Oct 02, 2001

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Deloitte
Teva
AstraZeneca
Argus Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.